drugset

Drugs / ABI-1179

Follow last change Apr 2026 re-read 3 minutes ago

ABI-1179

Developed for: genital herpes simplex type 2 infectious disorder
Investigated by: Assembly Biosciences

Trials 1

today NCT06698575 · Ph 1

20252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT06698575	Dec 2024 → Jan 2026	genital herpes simplex type 2 infectious disorder	Assembly Biosciences	Completed	No outcome recorded

News releases announcing trial results or a regulatory action · 4

Date	Issuer	Release
2025-12-08	Assembly Biosciences	Results Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes assemblybio.com ↗ 98% reduction in HSV-2 shedding rate, >99% reduction in high viral load shedding rate and 91% reduction in virologically confirmed genital lesion rate observed in 50 mg weekly oral dose of ABI-1179, exceeding expectations for the study
2025-07-26	Assembly Biosciences	Results Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop assemblybio.com ↗
2025-02-20	Assembly Biosciences	Results Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes assemblybio.com ↗ A half-life of approximately four days and high exposure across the dose range evaluated exceeded Assembly Bio’s targets for a once-weekly oral dosing profile.
2024-07-15	Assembly Biosciences	Results Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop assemblybio.com ↗

All press releases naming this drug 6 releases

Date	Issuer	Release
2026-04-09	Assembly Biosciences	Assembly Biosciences Highlights Presentations on Positive Phase 1b Data for ABI-5366 and ABI-1179 in Recurrent Genital Herpes at ESCMID Global 2026 assemblybio.com ↗
2025-12-08	Assembly Biosciences	Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes assemblybio.com ↗
2025-07-26	Assembly Biosciences	Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop assemblybio.com ↗
2025-06-30	Assembly Biosciences	Assembly Biosciences Doses First Participant in Phase 1b Portion of Phase 1a/b Clinical Trial of Investigational Long-Acting Herpes Simplex Virus Helicase-Primase Inhibitor ABI-1179 assemblybio.com ↗
2025-02-20	Assembly Biosciences	Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor ABI-1179 in Development for Recurrent Genital Herpes assemblybio.com ↗
2024-07-15	Assembly Biosciences	Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop assemblybio.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	ABI-1179	ClinicalTrials.gov intervention name — accepted as the source's own label NCT06698575 ↗
Route	Oral	“Once daily tablet dosing (SAD), or weekly tablet dosing over 29 days (MAD)” NCT06698575 ↗